Quick Answer
Convalescent plasma is plasma collected from people who have recovered from a specific infection and carry antibodies against that illness. The large-scale COVID-19 convalescent plasma programs have largely wound down, but convalescent plasma is still collected for certain conditions and ongoing research. Qualification requires documented recovery from a specific illness with confirmed antibody presence. Pay is typically the same as standard plasma donation ($50-$100 per visit), though some specialty programs offer higher compensation. The donation process is nearly identical to regular plasmapheresis.
What Is Convalescent Plasma?
Convalescent plasma is a type of blood plasma that contains specific antibodies produced by a donor's immune system after recovering from an infection. The concept is straightforward:
- Person gets sick: Your body fights an infection (virus, bacteria, or other pathogen)
- Person recovers: During recovery, your immune system produces antibodies -- specialized proteins that recognize and attack the specific pathogen
- Antibodies remain in plasma: Even after you feel completely well, these antibodies persist in your blood plasma for weeks, months, or even years
- Plasma is collected: Your antibody-rich plasma is collected through plasmapheresis (the same process as standard plasma donation)
- Plasma is transfused to patients: Patients who are currently fighting the same infection -- especially those with weakened immune systems -- receive your plasma to boost their antibody levels
The History of Convalescent Plasma
Convalescent plasma therapy is not new. It has been used for over 100 years:
- 1918 Spanish Flu: One of the earliest documented uses of convalescent plasma in a pandemic setting
- SARS (2003): Used in limited trials during the SARS-CoV-1 outbreak
- Ebola (2014-2016): Tested as an experimental treatment during the West African Ebola outbreak
- COVID-19 (2020-2023): The largest convalescent plasma program in history, with millions of units collected worldwide
- Ongoing research: Studies continue for various infectious diseases and immunodeficiency conditions
As an Amazon Associate, we earn from qualifying purchases.
Essential Products for Plasma Donors
Current Status: The Post-COVID Landscape (2026)
During the COVID-19 pandemic, convalescent plasma collection became a massive nationwide effort. Here is where things stand in 2026:
What Has Changed
- Emergency Use Authorization (EUA) expired: The FDA's COVID-19 convalescent plasma EUA, which allowed broad use in hospitalized patients, has been scaled back significantly
- Large-scale collection wound down: The dedicated COVID convalescent plasma collection programs at most blood banks and plasma centers have ended
- Routine use discontinued: COVID convalescent plasma is no longer a standard treatment for most hospitalized COVID patients, as other therapies (monoclonal antibodies, antiviral medications) have proven more effective for the general population
What Continues
- Immunodeficient patients: The FDA still authorizes COVID convalescent plasma for immunocompromised patients who cannot mount their own antibody response. This is a smaller but critical patient population
- Research programs: Academic medical centers and pharmaceutical companies continue collecting convalescent plasma for ongoing studies
- Other diseases: Convalescent plasma programs exist for conditions beyond COVID, including certain rare infections and as a treatment approach for emerging pathogens
- Preparedness infrastructure: The pandemic demonstrated the value of rapid convalescent plasma collection, so public health systems maintain the framework for future outbreaks
Premium Resource
Plasma Donor Pro Toolkit
90-day earning playbook, bonus stacking strategy, 2026 tax guide & deduction checklist. Earn $2,000+ in your first 3 months.
Get the Pro Toolkit — $19Current Medical Uses of Convalescent Plasma
While the pandemic-era mass collection has wound down, convalescent plasma remains a medically important product in specific scenarios:
Active Clinical Uses
| Use Case | Status | Patient Population |
|---|---|---|
| COVID-19 (immunodeficient) | FDA authorized | Patients with B-cell deficiencies, transplant recipients, and others who cannot produce their own antibodies |
| Emerging infections | Research / emergency use | Patients with novel infections where no specific treatment exists |
| Rare infections | Case-by-case | Patients with unusual pathogens where standard treatments are unavailable |
| Hyperimmune globulin production | Manufacturing | Convalescent plasma is processed into concentrated antibody products for broader distribution |
How Convalescent Plasma Helps Immunodeficient Patients
The most important current use is for immunocompromised patients. Here is why convalescent plasma is critical for this group:
- Cannot make their own antibodies: Patients with B-cell deficiencies, those on immunosuppressive drugs (transplant recipients, autoimmune disease patients), and those undergoing chemotherapy cannot mount an effective antibody response to infections
- Vaccines may not work: Even with vaccination, these patients often fail to develop protective antibodies. Convalescent plasma provides the antibodies their body cannot produce
- Monoclonal antibodies are limited: Some monoclonal antibody treatments have lost effectiveness against newer virus variants. Convalescent plasma from recently recovered donors may contain antibodies against current strains
- Bridge therapy: Convalescent plasma can serve as a bridge treatment while a patient's immune system recovers (for example, after bone marrow transplant)
How Convalescent Plasma Differs from Standard Plasma Donation
The actual donation process is nearly identical to standard plasmapheresis, but there are key differences in eligibility, testing, and purpose:
| Feature | Standard Plasma Donation | Convalescent Plasma Donation |
|---|---|---|
| Eligibility | Any healthy adult meeting standard criteria | Must have recovered from specific illness with documented antibodies |
| Testing | Standard viral marker testing | Standard testing PLUS antibody titer testing for the target illness |
| Collection process | Standard plasmapheresis (45-90 min) | Identical plasmapheresis process (45-90 min) |
| Frequency | Up to twice per week (FDA limit) | Varies by program; some limit collections to ensure high antibody titers |
| Use of plasma | Pharmaceutical manufacturing (immunoglobulin, albumin) | Direct transfusion to patients OR manufacturing of hyperimmune globulin |
| Where collected | Commercial plasma centers | Blood banks, hospital donation centers, and some commercial centers with specialty programs |
| Compensation | $50-$100 per visit | Typically same; some specialty programs pay more |
The Antibody Titer Factor
The key additional requirement for convalescent plasma is antibody testing. Not every recovered patient has sufficiently high antibody levels to make their plasma therapeutically useful:
- High titer = preferred: Plasma with high antibody concentrations (high titer) is most effective for patient treatment
- Timing matters: Antibody levels typically peak 2-6 weeks after recovery and may decline over months. Earlier donation after recovery often yields higher titers
- Individual variation: Antibody response varies widely between individuals. Some people produce very high levels; others produce minimal antibodies even after confirmed infection
- Booster effect: For COVID convalescent plasma, donors who were both infected AND vaccinated often have the highest and most diverse antibody levels
Who Qualifies to Donate Convalescent Plasma
Qualification for convalescent plasma donation requires meeting all standard plasma donation criteria PLUS additional illness-specific requirements:
Standard Requirements (Same as Regular Plasma)
- Age 18-69 (varies by program; some accept up to 75)
- Weight at least 110 lbs
- Generally good health
- No high-risk behaviors for bloodborne infections
- Pass standard vital sign screening (blood pressure, pulse, temperature)
- Meet protein and hematocrit requirements
Additional Convalescent-Specific Requirements
- Documented prior infection: You must have a confirmed positive test result (PCR, antigen, or other accepted diagnostic test) for the target illness
- Full recovery: You must be completely recovered from the illness. Most programs require being symptom-free for at least 14 days (some require 28 days)
- Antibody confirmation: Your blood will be tested to confirm the presence and concentration of target antibodies. Only donors with sufficiently high titers are accepted
- Time window: Some programs prefer donors within a specific window after recovery (for example, 2-6 months) when antibody levels are highest
- No current immunosuppressive treatment: You must not be taking medications that suppress your immune system, as these could lower antibody levels
How to Find Convalescent Plasma Programs
- American Red Cross: Check redcrossblood.org for any active convalescent plasma programs in your area
- Local blood banks: Contact community blood banks directly. They may have smaller, targeted programs
- Hospital research programs: Academic medical centers often have ongoing convalescent plasma research studies. Check ClinicalTrials.gov for active studies
- Your doctor: If you recently recovered from an illness, ask your healthcare provider if convalescent plasma donation programs exist for your condition
Pay and Compensation for Convalescent Plasma
Compensation for convalescent plasma donation varies depending on where and how you donate:
Compensation by Program Type
| Program Type | Typical Compensation | Notes |
|---|---|---|
| Commercial plasma center (standard) | $50-$100 per visit | Same rate as regular plasma; your convalescent status may not be tracked |
| Blood bank convalescent program | Usually unpaid (volunteer) | American Red Cross and nonprofit blood banks typically do not pay. May offer gift cards or small incentives |
| Hospital research study | $50-$500+ per visit | Varies widely by study. Some pay significantly more than standard plasma rates |
| Specialty pharmaceutical collection | $75-$200 per visit | Some pharmaceutical companies run dedicated convalescent programs with premium pay for high-titer donors |
Maximizing Compensation
- Standard commercial donation: If no specialty program is available in your area, donate at a commercial plasma center as a regular donor. Your compensation will be the same as standard plasma donation ($50-$100 per visit). The antibodies in your plasma still benefit patients through pharmaceutical manufacturing
- Research study enrollment: Search ClinicalTrials.gov for convalescent plasma studies. These often pay more than standard donation and may also cover travel expenses
- Specialty programs: Some pharmaceutical companies (like Grifols, CSL Behring) periodically run premium programs for donors with specific high-titer antibodies. Contact your local centers to ask about any specialty programs
- Negotiate timing: If you have confirmed high-titer antibodies, some programs will prioritize your appointments or offer incentives for frequent donation during the optimal antibody window
Frequently Asked Questions
Is convalescent plasma still being collected in 2026?
Yes, but on a much smaller scale than during the COVID-19 pandemic. The large-scale emergency collection programs have wound down. However, convalescent plasma is still collected for immunodeficient COVID patients, ongoing research studies, and occasionally for other infectious diseases. The infrastructure remains in place for future outbreaks.
How is convalescent plasma different from regular plasma donation?
The physical donation process is identical -- standard plasmapheresis taking 45-90 minutes. The difference is in eligibility and testing: convalescent donors must have documented recovery from a specific infection, be symptom-free for at least 14 days, and have confirmed antibodies at sufficient levels (high titer). The plasma is used for direct patient transfusion or hyperimmune globulin manufacturing rather than standard pharmaceutical production.
Does convalescent plasma donation pay more than regular plasma?
It depends on the program. At standard commercial plasma centers, convalescent donors earn the same $50-$100 per visit as regular donors. However, some specialty pharmaceutical programs and research studies offer higher compensation ($75-$500+ per visit) for donors with high-titer antibodies. Nonprofit blood bank programs are typically unpaid.
Who qualifies to donate convalescent plasma?
You must meet all standard plasma donation criteria (age, weight, health) plus additional requirements: documented positive test for the target illness, complete symptom-free recovery (typically 14-28 days), and confirmed antibodies at sufficient concentration through a blood test. Some programs have time windows, preferring donors within 2-6 months of recovery when antibody levels are highest.
Can I donate convalescent plasma if I was vaccinated but never sick?
Generally, no. Convalescent plasma specifically refers to plasma from people who recovered from an actual infection. Vaccination produces antibodies, but vaccine-induced antibodies alone typically do not qualify for convalescent plasma programs. However, donors who were both infected AND vaccinated often have the strongest antibody response and are preferred by many programs. Check with specific programs for their exact criteria.